Considering that Wnt/β-catenin signaling is highly activated and contributes to prostate cancer progression [30], targeting SOX30 to inhibit Wnt/β-catenin signaling may have a potential application in prostate cancer therapy. Here, SOX30 is linked to prostate carcinoma.